Faraday Pharmaceuticals to Host Satellite Symposium at SCAI 2025 on Exploring New Frontiers in Reducing Ischemia-Reperfusion Injury


SEATTLE, April 24, 2025 (GLOBE NEWSWIRE) -- Faraday Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on preventing heart failure by reducing myocardial damage in acute ST-elevation myocardial infarction (STEMI) through the reduction of ischemia-reperfusion injury (IRI), today announced that it will host a symposium during the Society for Cardiovascular Angiography and Interventions (SCAI) 2025 Scientific Sessions being held May 1-3, 2025, in Washington, D.C.

Visit link:
Faraday Pharmaceuticals to Host Satellite Symposium at SCAI 2025 on Exploring New Frontiers in Reducing Ischemia-Reperfusion Injury

Related Posts